Correction to “Polysialic-Acid-based Micelles Promote Neural Regeneration in Spinal Cord Injury Therapy”

Xiao-Juan Wang,Chen-Han Peng,Shuo Zhang,Xiao-Ling Xu,Gao-Feng Shu,Jing Qi,Ya-Fang Zhu,De-Min Xu,Xu-Qi Kang,Kong-Jun Lu,Fei-Yang Jin,Ri-Sheng Yu,Ying,Jian You,Yong-Zhong Du,Jian-Song Ji

DOI: https://doi.org/10.1021/acs.nanolett.1c04394

IF: 10.8

2021-01-01

Nano Letters

Abstract:Spinal cord injury (SCI) routinely causes the immediate loss and disruption of neurons followed by complicated secondary injuries, including inflammation, oxidative stress, and dense glial scar formation. Inhibitory factors in the lesion scar and poor intrinsic neural regeneration capacity restrict functional recovery after injury. Minocycline, which has neuroprotective activity, can alleviate secondary injury, but the long-term administration of this drug may cause toxicity. Polysialic acid (PSA) is a large cell-surface carbohydrate that is critical for central nervous system development and is capable of promoting precursor cell migration, axon path finding, and synaptic remodeling; thus, PSA plays a vital role in tissue repair and regeneration. Here, we developed a PSA-based minocycline-loaded nanodrug delivery system (PSM) for the synergistic therapy of spinal cord injury. The prepared PSM exerted marked anti-inflammatory and neuroprotective activities both in vitro and in vivo. The administration of PSM could significantly protect neurons and myelin sheaths from damage, reduce the formation of glial scar, recruit endogenous neural stem cells to the lesion site, and promote the regeneration of neurons and the extension of long axons throughout the glial scar, thereby largely improving the locomotor function of SCI rats and exerting a superior therapeutic effect. The findings might provide a novel strategy for SCI synergistic therapy and the utilization of PSA in other central nervous system diseases.